Strongbridge Biopharma (NASDAQ:SBBP)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a note issued to investors on Thursday. They currently have a $18.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective indicates a potential upside of 129.30% from the company’s previous close.
A number of other research analysts have also weighed in on SBBP. Zacks Investment Research lowered Strongbridge Biopharma from a “hold” rating to a “sell” rating in a report on Thursday, September 28th. ValuEngine lowered Strongbridge Biopharma from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Cantor Fitzgerald initiated coverage on Strongbridge Biopharma in a report on Tuesday, December 5th. They set a “buy” rating and a $14.00 price objective on the stock. Finally, BidaskClub raised Strongbridge Biopharma from a “hold” rating to a “buy” rating in a report on Wednesday, December 27th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $12.81.
Strongbridge Biopharma (NASDAQ SBBP) traded down $0.50 during trading hours on Thursday, hitting $7.85. The stock had a trading volume of 157,100 shares, compared to its average volume of 214,555. The firm has a market capitalization of $299.03, a price-to-earnings ratio of -2.31 and a beta of 2.60. The company has a debt-to-equity ratio of -1.89, a quick ratio of 4.61 and a current ratio of 4.70. Strongbridge Biopharma has a 1-year low of $2.10 and a 1-year high of $8.85.
Hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp acquired a new position in Strongbridge Biopharma during the second quarter worth $331,000. Citigroup Inc. acquired a new position in Strongbridge Biopharma during the second quarter worth $338,000. Lyon Street Capital LLC acquired a new position in Strongbridge Biopharma during the third quarter worth $2,862,000. Northern Trust Corp acquired a new position in Strongbridge Biopharma during the second quarter worth $1,462,000. Finally, TIAA CREF Investment Management LLC acquired a new position in Strongbridge Biopharma during the second quarter worth $449,000. 63.96% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: “HC Wainwright Reaffirms Buy Rating for Strongbridge Biopharma (SBBP)” was first reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3144279/hc-wainwright-reaffirms-buy-rating-for-strongbridge-biopharma-sbbp.html.
Strongbridge Biopharma Company Profile
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.
Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.